tradingkey.logo

BioLife Solutions Inc

BLFS
26.040USD
-0.250-0.95%
Close 11/11, 16:00ETQuotes delayed by 15 min
1.25BMarket Cap
LossP/E TTM

BioLife Solutions Inc

26.040
-0.250-0.95%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of BioLife Solutions Inc

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BioLife Solutions Inc's Score

Industry at a Glance

Industry Ranking
29 / 209
Overall Ranking
92 / 4608
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 10 analysts
Buy
Current Rating
32.100
Target Price
+22.10%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

BioLife Solutions Inc Highlights

StrengthsRisks
BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Growing
The company is in a growing phase, with the latest annual income totaling USD 82.25M.
Undervalued
The company’s latest PE is -469.44, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.24M shares, decreasing 2.41% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 521.80K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-11

The company's current financial score is 8.90, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 28.07M, representing a year-over-year decrease of 8.19%, while its net profit experienced a year-over-year decrease of 136.47%.

Score

Industry at a Glance

Previous score
8.90
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

6.69

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.81

BioLife Solutions Inc's Company Valuation

Currency: USD Updated: 2025-11-11

The company’s current valuation score is 7.43, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -469.44, which is -99.19% below the recent high of -3.78 and -0.96% above the recent low of -473.95.

Score

Industry at a Glance

Previous score
7.43
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 29/209
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-11

The company’s current earnings forecast score is 8.40, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for BioLife Solutions Inc is 32.00, with a high of 34.00 and a low of 30.00.

Score

Industry at a Glance

Previous score
8.40
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts
Buy
Current Rating
32.100
Target Price
+22.10%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
BioLife Solutions Inc
BLFS
10
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Dexcom Inc
DXCM
30
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-11

The company’s current price momentum score is 6.34, which is lower than the Healthcare Equipment & Supplies industry's average of 7.18. Sideways: Currently, the stock price is trading between the resistance level at 28.61 and the support level at 24.48, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.51
Change
-0.17

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.590
Neutral
RSI(14)
42.917
Neutral
STOCH(KDJ)(9,3,3)
23.872
Neutral
ATR(14)
1.230
Low Volatility
CCI(14)
-142.360
Sell
Williams %R
86.683
Oversold
TRIX(12,20)
0.041
Sell
StochRSI(14)
11.502
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
26.570
Sell
MA10
27.014
Sell
MA20
27.524
Sell
MA50
26.592
Sell
MA100
24.659
Buy
MA200
24.408
Buy

Institutional Confidence

Currency: USD Updated: 2025-11-11

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 104.42%, representing a quarter-over-quarter increase of 4.69%. The largest institutional shareholder is The Vanguard, holding a total of 2.96M shares, representing 6.15% of shares outstanding, with 0.27% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Casdin Capital, LLC
6.71M
-12.97%
BlackRock Institutional Trust Company, N.A.
5.08M
+0.25%
T. Rowe Price Investment Management, Inc.
4.25M
+215.04%
Invesco Advisers, Inc.
3.46M
+3.80%
The Vanguard Group, Inc.
Star Investors
2.89M
+3.33%
State Street Investment Management (US)
1.41M
-1.73%
Fred Alger Management, LLC
1.25M
-18.60%
MFS Investment Management
1.10M
+44.13%
Rockefeller Capital Management
1.03M
+6.45%
Columbia Wanger Asset Management, LLC
997.60K
+13.19%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-11

The company’s current risk assessment score is 6.57, which is higher than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 1.93. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
6.57
Change
0
Beta vs S&P 500 index
1.93
VaR
+6.17%
240-Day Maximum Drawdown
+27.55%
240-Day Volatility
+60.65%

Return

Best Daily Return
60 days
+4.07%
120 days
+10.28%
5 years
+42.77%
Worst Daily Return
60 days
-4.60%
120 days
-5.63%
5 years
-28.71%
Sharpe Ratio
60 days
+1.00
120 days
+0.85
5 years
+0.21

Risk Assessment

Maximum Drawdown
240 days
+27.55%
3 years
+65.52%
5 years
+85.14%
Return-to-Drawdown Ratio
240 days
-0.10
3 years
+0.27
5 years
-0.09
Skewness
240 days
+0.23
3 years
-0.41
5 years
+0.57

Volatility

Realised Volatility
240 days
+60.65%
5 years
+68.44%
Standardised True Range
240 days
+4.89%
5 years
+5.62%
Downside Risk-Adjusted Return
120 days
+171.10%
240 days
+171.10%
Maximum Daily Upside Volatility
60 days
+23.48%
Maximum Daily Downside Volatility
60 days
+25.24%

Liquidity

Average Turnover Rate
60 days
+1.17%
120 days
+1.17%
5 years
--
Turnover Deviation
20 days
+32.09%
60 days
+23.32%
120 days
+23.40%

Peer Comparison

Healthcare Equipment & Supplies
BioLife Solutions Inc
BioLife Solutions Inc
BLFS
7.94 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Boston Scientific Corp
Boston Scientific Corp
BSX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.55 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI